Cita APA

Li, T., LoRusso, P., Maitland, M. L., Ou, S. I., Bahceci, E., Ball, H. A., . . . Tolcher, A. (2016). First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. J Hematol Oncol.

Chicago Style Citation

Li, Tianhong, Patricia LoRusso, Michael L. Maitland, Sai-Hong Ignatius Ou, Erkut Bahceci, Howard A. Ball, Jung Wook Park, Geoffrey Yuen, i Anthony Tolcher. "First-in-human, Open-label Dose-escalation and Dose-expansion Study of the Safety, Pharmacokinetics, and Antitumor Effects of an Oral ALK Inhibitor ASP3026 in Patients With Advanced Solid Tumors." J Hematol Oncol 2016.

Cita MLA

Li, Tianhong, et al. "First-in-human, Open-label Dose-escalation and Dose-expansion Study of the Safety, Pharmacokinetics, and Antitumor Effects of an Oral ALK Inhibitor ASP3026 in Patients With Advanced Solid Tumors." J Hematol Oncol 2016.